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In the past decade, there has been remarkable progress in understanding of the roles of Cl− channels in the development of human
diseases. Genetic studies in humans have identified mutations in the genes encoding Cl− channels which lead to a loss of Cl− channel
activity. These mutations are responsible for the development of a variety of deleterious diseases in muscle, kidney, bone and brain
including myotonia congenita, dystrophia myotonica, cystic fibrosis, osteopetrosis and epilepsy. Recent studies indicate that some diseases
may develop as a result of Cl− channel activation. There is growing evidence that the progression of glioma in the brain and the growth of
the malaria parasite in red blood cells may be mediated through Cl− channel activation. These findings suggest that Cl− channels may be
novel targets for the pharmacological treatment of a broad spectrum of diseases. This review discusses the proposed roles of abnormal Cl−
channel activity in the pathogenesis of human diseases.
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Chloride channels are pore-forming membrane proteins that
allow the passive transport of Cl− across biological membranes.
They are ubiquitously expressed in almost all eukaryotic cells
[1]. In the plasma membrane, Cl− channels are essential for the
regulation of cell volume, the transepithelial transport of salt
and water as well as the modulation of the electrical excitability
in neurons. Cl− channels are also found in membranes of
intracellular organelles such as lysosomes and endosomes [2].
In these compartments, Cl− channels play a key role in the
regulation of organelle volume and pH, factors which are
important for the delivery of membrane transport proteins to the
plasma membrane.
Cl− channels open in a process called gating and have been
functionally classified according to their gating mechanisms,
depending on changes in the membrane electric potential
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ulator (CFTR) Cl− channels), increases in intracellular Ca2+
levels (Ca2+-activated Cl− channels, CaCC channels), and
binding of a ligand (glycine- or γ-aminobutyric acid (GABA)-
activated Cl− channels). Furthermore, Cl− channels can also be
activated by an increase in cell volume, extracellular acidifica-
tion, the degree of phosphorylation and the binding of ATP.
Despite the variety of functional Cl− channels, molecular
biology has revealed only three well-established gene families
of Cl− channels: ClC, CFTR and ligand-gated Cl− channels [3].
It should be noted that the CFTR belongs to the gene family of
ABC transporters, which normally function as transport
ATPases. CFTR is the only member which is known to function
as an ion channel [3]. The discrepancy between the number of
functional Cl− channels and actual cloned proteins may be
related to the fact that there are no “Cl− channel signature”
sequences conserved among the known channel families. Thus,
it is likely that entire families of Cl− channels have not yet been
identified.
The role of Cl− channels in the physiology of neurons,
muscle and epithelial cells has been extensively studied [1].
Opening of Cl− channels in the plasma membrane shifts the
membrane potential towards negative values resulting in
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cells. Defective Cl− channel activity leads to hyperexcitability
and appears to be the principal cause for the development of
myotonia congenita, dystrophia myotonica, hereditary hyper-
ekplexia, epilepsy and chronic insomnia. While the most
important role of Cl− channels in neurons and muscle cells is to
regulate the excitability, the primary function of these channels
in epithelial cells is to mediate the transepithelial transport of
salt and water. There is increasing evidence that defective Cl−
transport in epithelial cells is a critical event that leads to the
development of various forms of cystic fibrosis (CF) and Bartter
syndrome [2]. Cl− channels in intracellular compartments have
a distinct role in maintaining pH of these compartments.
Opening of Cl− channels provides the Cl− influx that is required
for the acidification by H+-ATPase. Numerous studies have
demonstrated that a low pH is essential for the insertion of
transport proteins into the plasma membrane, and the cellular
uptake of hormones and vitamins [3]. Defective Cl− channels in
intracellular compartments contribute importantly to the
development of osteopetrosis in the bone and Dent's disease
in the kidney. Thus, Cl− channel dysfunction may play an
important role in the pathogenesis of many diseases. Genetic
studies in humans have identified mutations in the genes
encoding Cl− channels that are directly responsible for the
development of these diseases [2,4]. In addition, there is
emerging evidence that a loss of Cl− channel activity may also
mediate the development of chronic pancreatitis, bronchiectasis,
congenital bilateral aplasia of vas deferens, alcoholism, cataract
and Best's disease. While the Cl− channel proteins involved
have been cloned, the cellular mechanisms linking Cl− channel
dysfunction to the pathogenesis of these diseases are still
unknown.
Recent studies indicate that in addition to the inhibition of
channel activity, some diseases such as glioma and malaria mayFig. 1. Cl− channels and human diseases. A cartoon shows the cellular locations, the ty
Cl− channel activity. Arrows indicate the direction of Cl− transport under normal ph
(blue arrows).develop as a result of stimulation of Cl− channel activity [5–8].
These findings provide strong support for the concept that
abnormal Cl− channel activity may be a novel target for the
therapeutic intervention in a broad spectrum of diseases. Fig. 1
illustrates human diseases known to be associated with
abnormal Cl− channel activity.
A comprehensive description of molecular structure and the
physiology of Cl− channels is beyond the scope of this review
and can be found in excellent recent reviews [1,2]. The purpose
of this review is to give a short overview and discuss the
proposed roles of abnormal Cl− channel activity in a variety of
human diseases.
2. Dysfunction of Cl− channels in the plasma membrane
2.1. Myotonia congenita
Myotonia congenita is a hereditary muscle disorder charac-
terized by muscle stiffness and a delay in relaxation after a
voluntary muscle contraction. There are two forms of myotonia
congenita: autosomal-recessive Becker disease and autosomal-
dominant Thomsen disease. Both disorders are caused by
mutations in the gene CLCN1 that encodes a subunit of the
skeletal muscle Cl− channel ClC-1 (Table 1). The molecular
mechanism involved in the pathogenesis of myotonia congenita
is well understood [9]. The Cl− conductance mediated through
activation of ClC-1 channels is severely reduced in patients with
myotonia congenita [10,11]. Because the Cl− conductance
contributes significantly to the resting membrane conductance
and helps to inhibit electrical activity, a loss of ClC-1 channel
activity leads to muscle hyperexcitability and anomalous firing
of action potentials. To date, more than 80 different mutations in
CLCN1 gene have been identified in myotonia congenita, and
most of them result in a recessive form of the disease [9,12].pe of Cl− channel and diseases known to be associated with a downregulation of
ysiologic conditions. In glioma and malaria, Cl− channel activity is upregulated
Table 1
Cl− channelopathies
Cl− channel Human disease Reference
ClC-1 Myotonia congenita Becker [10]
Myotonia congenita Thomsen [102]
Dystrophia myotonica 1 [18,20]
Dystrophia myotonica 2 [18,19]
ClC-2 Childhood absence epilepsy type 3 [103]
Juvenile absence epilepsy [103]
Juvenile myoclonic epilepsy [103]
Epilepsy with grand mal
seizures on awakening
[103]
ClC-Kb Bartter Syndrome III [104]
ClC-Ka, ClC-Kb
(Barttin)
Bartter Syndrome IV or BSND [76,77]
ClC-5 Dent's disease [105–107]
ClC-7 Autosomal dominant osteopetrosis [83]
Autosomal recessive osteopetrosis [82]
CFTR Cystic fibrosis [108]
Idiopathic chronic pancreatitis [109–111]
Bronchiectasis [35,112–114]
Congenital bilateral absence
of vas deferens
[40,115–117]
Bestrophin Best's disease [69,118,119]
Adult-onset vitelliform
macular dystrophy
[120]
Concentric annular
macular dystrophy
[120]
Unknown Cataract [57–60]
GABAA Juvenile myoclonic epilepsy [121]
Childhood absence epilepsy type 2 [122]
Generalized epilepsy with
febrile seizures plus
[123]
Severe myoclonic epilepsy
in infancy
[124]
Alcoholism [125,126]
Insomnia [49]
GlyR Hereditary hyperekplexia [41,44,127,128]
Cl− channel proteins and human diseases associated with mutations in these
proteins.
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Dystrophia myotonica (DM) is an autosomal-dominant
inherited disease that primarily affects muscles and the nervous
system, causing myotonia, heart block and cataract [13]. Similar
to myotonia congenita, muscles in patients with DM have the
ability to contract but have decreasing power to relax. The most
important difference between DM and myotonia congenita is
that patients with DM develop a severe muscle dystrophy and
weakness. Two genetic forms of dystrophia myotonica have
been described: DM1 and DM2 (Table 1). Genetic studies
firmly established that the functional defects in DM1 and DM2
are caused by DNA expansion mutations [14–17]. These DNA
repeats do not encode any portion of the protein, but when
transcribed, cause the mRNA to be retained in the nucleus [18].
Recent studies have demonstrated that nuclear accumulation of
mRNA leads to an irregular splicing of a ClC-1 pre-mRNA
[19–21]. This may cause inhibition of the Cl− conductance as
observed in patients with DM [22]. Thus, a loss of ClC-1
channel activity due to aberrant pattern of ClC-1 splicing
appears to be the dominant mechanism responsible for thedevelopment of myotonia in both forms of dystrophia
myotonica [23].
2.3. Cystic fibrosis
Cystic fibrosis (CF) is the most common autosomal-
recessive disease in Caucasians that leads to early death.
Mucous secretions of CF patients are abnormally viscid leading
to the obstruction of the luminal space and recurrent cycles of
inflammation and fibrosis, which ultimately destroy the affected
organs. The disease is caused by mutations in the CFTR gene
(Table 1). This gene encodes a Cl− channel that is activated by
increases in intracellular cAMP levels [24]. CFTR is primarily
localized at the apical surface of epithelial cells lining the
airway, gut, exocrine glands, where it regulates the transepithe-
lial salt and water transport [25]. Although the physiology of
CFTR is complex, it appears that a loss in CFTR activity is a
primary event which is responsible for defective Cl− uptake into
the epithelial cells and the development of CF symptoms [26].
Two models have been proposed to explain defective salt
transport in CF patients [27]. In one model, diminished Cl−
reabsorption through CFTR causes a decrease in Na+ uptake
through the epithelial Na+ channels (ENaC) in the plasma
membrane resulting in an increased salt content in the luminal
space. In this high-salt model, elevated salt concentration may
ultimately lead to a severe obstruction of secretory functions in
epithelial cells. In the alternative model, the increased Na+
absorption through ENaC mediates an increase in Cl−
reabsorption through non-CFTR dependent Cl− absorptive
pathways, which leads to dehydration of airway surfaces and
defective mucociliary transport. This model is supported by the
recent studies in which mice with airway-specific overexpres-
sion of ENaC develop a severe lung disease similar to CF [28].
Regardless of which model of NaCl reabsorption is used to
explain the pulmonary deficiency in CF, there is a strong
consensus that patients with the disease lack the normal ability
to transport Cl− through CFTR in the airways.
More than 1000 mutations of CFTR gene have been reported
so far [29]. Some CFTR mutations have also been linked to
other diseases, such as chronic pancreatitis, congenital bilateral
absence of vas deferens, bronchiectasis, asthma, aspergillosis
and sinusitis [30]. These findings have led to the hypothesis that
inhibition of CFTR activity may play an important role in the
pathogenesis of many diseases in epithelial tissue.
2.4. Chronic pancreatitis
Pancreatitis is inflammation of the pancreas caused by
digestive enzymes that autodigest the pancreas itself. Several
groups have reported an increased prevalence of CFTR
mutations in patients with idiopathic chronic pancreatitis
(Table 1). While up to 30% of the patients with chronic
pancreatitis were found to have at least one CFTR mutation,
patients with two or more CFTR mutations appear to be at
higher risk [31,32].
Although the CFTR mutations may be involved in the
progression of chronic pancreatitis, the cellular mechanisms
407L. Puljak, G. Kilic / Biochimica et Biophysica Acta 1762 (2006) 404–413responsible for inflammation of the pancreas are not known. It has
been proposed that an inhibition of Cl− channel activity caused by
the CFTR mutations leads to a decrease in the ductal pH.
Subsequently, the ductal acidification may promote a defective
solubilization of proteins, inhibition of zymogen granule trafficking
and stimulation of the pancreatic enzyme, trypsinogen. This
concept is further supported with the finding that even a moderate
reduction inCFTR activity in a heterozygous state increases the risk
for chronic pancreatitis [30].
2.5. Bronchiectasis
Bronchiectasis is characterized by an abnormal irreversible
dilatation of bronchi and represents the end stage of a variety of
pathological processes that cause the destruction of the
bronchial wall and supporting tissues [33]. CFTR is expressed
in several cell types of the airway and mutations in the CFTR
gene have been found in several lung disorders [34].
Several lines of evidence suggest that mutations in the CFTR
gene may also contribute to the pathogenesis of bronchiectasis
(Table 1). In addition to defective CFTR activity, the
environmental factors and other genes may also be involved in
the development of this disease [35]. In contrast to these
findings, other studies indicate that the frequency of CFTR
mutations in patients with bronchiectasis was not significantly
higher than in general population [36,37]. These studies were
done with a small number of patients and imply that further
studies in a larger cohort of clinically well-defined patients are
needed. Thus, it is still unknown whether defective CFTR
activity in lung is involved in the pathogenesis of bronchiectasis.
2.6. Congenital bilateral aplasia of vas deferens
Congenital bilateral aplasia of the vas deferens (CBAVD)
leads to male infertililty. This disease is also characterized by
the presence of subclinical cystic fibrosis symptoms including
elevated sweat Cl− concentrations and sinusitis [38]. Further-
more, because the vas deferens is absent in most of male
patients with cystic fibrosis, CBAVD emerged as a primary
genital form of cystic fibrosis [39].
Mutations and the splice variants in the CFTR gene are found
in the majority of CBAVD patients (Table 1). While patients
with cystic fibrosis have mutations in both copies of the CFTR
gene, most patients with CBAVD have mutations in only one
copy of the gene [40]. Although CBAVD appears to be closely
associated with a loss of the CFTR activity, it is not known how
and by which mechanisms, Cl− channel dysfunction leads to an
early regression of the mesonephric duct and progressive male
infertility.
2.7. Hereditary hyperekplexia
Hyperekplexia, also known as hereditary startle disease, is
characterized by an exaggerated startle reflex, neonatal
hypertonia, nocturnal myoclonus and a chronic accumulation
of injuries caused by startle-induced falls. Both autosomal-
dominant and autosomal-recessive hyperekplexia are caused bymutation in the gene GLRA1 encoding the α-1 subunit of the
glycine receptor (Table 1). Mutations in the gene GLRB
encoding the β-subunit of the glycine receptor can also lead
to the development of autosomal-recessive hyperekplexia
[41,42].
The role of glycine-activated Cl− channels in the pathogen-
esis of hyperekplexia is well defined. Stimulation of Cl−
conductance by glycine facilitates fast inhibitory neurotrans-
mission in the brainstem and spinal cord, resulting in the
reduction of excitatory startle responses [43]. Mutations in both
subunits inhibit the binding of glycine to its receptor and reduce
the magnitude of the Cl− conductance [44]. Similar to myotonia
congenita and dystrophia myotonica, the reduction in Cl−
conductance leads to hyperexcitability of the pontomedullary
reticular neurons and abnormal spinal reciprocal inhibition.
2.8. Epilepsy
Epilepsy is a recurrent transient disturbance of brain function
resulting from hyperexcitability of neurons and is unrelated to
infection or acute cerebral insult. Idiopathic epilepsy accounts
for about 40% of the cases. Recent studies have provided
evidence that heterozygous mutations in a gene encoding for
Cl− channel ClC-2 (CLCN2) may be responsible for several
subtypes of idiopathic generalized epilepsy including childhood
absence epilepsy type 3, juvenile absence epilepsy, juvenile
myoclonic epilepsy and epilepsy with grand mal seizures on
awakening (Table 1). Other studies found no correlation
between mutations in the CLCN2 gene and epilepsy [45].
Thus, the role of ClC-2 in the pathogenesis of epilepsy is not
known for certain. In contrast to ClC-2, the evidence for the
involvement of synaptic GABAA-receptor Cl
− channels in the
pathogenesis of certain forms of epilepsies is firmly established
[46]. Specifically, mutations in GABRG2, the gene encoding
GABAA γ2-subunit, mediate several different types of epilep-
sies including juvenile myoclonic epilepsy, childhood absence
epilepsy 2, generalized epilepsy with febrile seizures plus and
its severe form of myoclonic epilepsy in infancy (Table 1).
The physiologic mechanisms responsible for the develop-
ment of epilepsy are well established. In the healthy brain,
physiologic stimulation of Cl− influx through Cl− channels
provides a mechanism for tonic inhibition of the electrical
activity in neurons. Consequently, dysfunction of either the
ClC-2 or the GABAA Cl
− channel activity may make neurons
more susceptible for excitation, and subsequently may induce
epilepsy. This model is further supported by the findings that
drugs used to treat epilepsy (i.e., barbiturates and benzodiaze-
pines, vigabatrine and tiagabine) function through stimulation
of GABA-mediated Cl− channels [47]. Conversely, drugs that
decrease the concentration of GABA in the brain by inhibiting
the synthesis of GABA cause seizures [48].
It should be noted that GABAA-receptors are composed from
the repertoire of 19 subunit variants and are widespread
throughout the brain. Thus, it is not surprising that a close
correlation exists between various subunit gene polymorphisms
and a broad spectrum of neuropsychiatric disorders, including
alcoholism, schizophrenia, anxiety, and bipolar affective
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animal models may provide more selective targets for the
treatment of neuropsychiatric disorders.
2.9. Chronic insomnia
Genetic studies have identified a missense mutation in the
gene encoding the β-3 subunit of the GABAA receptor
(GABRB3) in a patient with chronic insomnia who had a family
history of sleep problems [49] (Table 1). The patient was found
to be heterozygous for this mutation. Functional analysis of this
mutation revealed that the Cl− conductance evoked by GABA
decays faster in mutated channels than in wild-type channels.
These results indicate that mutations in the GABAA-receptors
may be involved in the pathogenesis of insomnia.
Consistent with these results, deletion of GABRB3 gene
inhibited the hypnotic response to oleamide in mice [50].
Furthermore, sleep disorders including insomnia have been
effectively treated with the therapeutic agents that stimulate
GABAA-receptor Cl
− channel activity [47]. These findings are
consistent with the hypothesis that a loss of GABA-mediated
Cl− channel activity may be directly responsible for abnormal
electrical activity of neurons and the development of insomnia.
The final confirmation of this hypothesis will require further
studies.
2.10. Alcoholism
Multiple lines of evidence suggest that GABAA-receptor Cl
−
channels are involved in many of the neurochemical pathways
contributing to alcohol use [51]. GABAA-receptor agonists tend
to potentiate the behavioral effects of alcohol, while GABAA-
receptor antagonists attenuate these effects. Furthermore,
GABAA-receptors have also been implicated in ethanol
tolerance and dependence [51]. The precise mechanism by
which GABA receptors mediate these effects of ethanol are still
unknown.
Recent studies found a close correlation between the
susceptibility for alcohol dependence and GABRA2, a gene
encoding the α-2 subunit of GABAA receptor (Table 1). Other
studies found no such correlation [52–54]. Similar to GABRA2,
the evidence for and against the involvement of GABA-
mediated inhibition in the susceptibility for alcohol dependence,
have also been obtained forGABRA6, another gene that encodes
the α-6 subunit of GABAA receptor [54, 55]. Consequently, it is
still unknown whether defective GABA-mediated Cl− channel
activity plays the dominant role in the susceptibility for alcohol
dependence.
2.11. Cataract
A cataract is a cloudy area in the lens of the eye that leads
to impaired vision. Studies in animals have clearly demon-
strated that the lens swelling precedes opacification [56].
Consequently, the ability of lens cells to maintain cell volume
within narrow physiologic limits is critical for the lens to
remain transparent. Stimulation of volume-activated Cl−channels in response to cell swelling plays a key role in the
regulation of cell volume. Several recent studies indicate that
inhibition of volume-activated Cl− channels by tamoxifen or
Cl− channel blockers in animals, causes the lens to swell and
opacify [57–60]. These results are consistent with the
hypothesis that reduced activity of volume-activated Cl−
channels in the plasma membrane of the lens cells may be
involved in the development of cataract.
In humans, there are reports that tamoxifen, an antiestrogen
frequently used in the treatment of breast cancer, increases the
risk of cataract after prolonged use [61–63]. However, in other
studies, no such risk is observed [64–66]. These findings
suggest that the role of volume-activated Cl− channels in the
pathogenesis of cataract in humans still needs to be defined.
2.12. BestTs disease
Best's disease or juvenile-onset vitelliform macular dystro-
phy, is an autosomal-dominant disease of the central retina
characterized by macular lesions resembling the yolk of an egg
(‘vitelliform’). This disease is caused by mutations in the VMD2
gene that encodes bestrophin, a transmembrane protein with
putative Ca2+-dependent Cl− channel activity in the retinal
pigment epithelium [67, 68] (Table 1). Mutations in the VMD2
gene also appear to be involved in an adult-onset vitelliform
macular dystrophy and concentric annular macular dystrophy
(Table 1).
The cellular mechanisms responsible for the retinal degen-
eration in Best's disease are still poorly understood. Recent
studies have demonstrated that mutated bestrophin forms a
defective plasma membrane Ca2+-dependent Cl− channel [69].
Several lines of evidence suggest that Cl− channel activity
mediated by the bestrophins may have multiple functions, both
at the plasma membrane and in intracellular organelles. In the
plasma membrane of the retinal pigment epithelium, Cl−
channels regulate the composition of the extracellular fluid as
well as cell volume. Defects in Cl− channel activity in the
plasma membrane may result in retinal degeneration as a
consequence of abnormal regulation of cell volume and/or the
extracellular fluid composition [70]. It is proposed that plasma
membrane transport by the retinal pigment epithelium helps
maintain the composition of this fluid within a range that
supports phototransduction [71]. Other studies are consistent
with the concept that bestrophins regulate the ionic environment
of inside organelles in the endosomal-lysosomal pathway, and
retinal degeneration may result from defects in lysosomal
trafficking or function [70].
2.13. Bartter syndrome
Bartter syndrome is a genetically heterogeneous disorder
caused by defective renal tubular electrolyte transport [72,73].
Five genotypes of Bartter's syndrome have been described so
far, but only Bartter types III and IV are caused by defective
activity of ClC-Ka and ClC-Kb channels. Both Cl− channels are
members of the ClC family, and they both need barttin for the
functional expression in kidney cells. Barttin is a small
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with ClC-Ka and ClC-Kb.
Bartter syndrome type III or classic Bartter syndrome, is
caused by mutations in the CLCNKB, human gene encoding
ClC-Kb (Table 1). Typically, the onset of the syndrome occurs
during infancy or childhood, with a characteristic set of
metabolic abnormalities including hypokalemia, metabolic
alkalosis, hyperreninemia and hyperaldosteronism. The disease
develops as a result of decreased renal Cl− transport that leads to
a reduction of NaCl reabsorption from urine. A large amount of
NaCl and water are lost in urine resulting in stimulation of
secretion of renin, angiotensin II and aldosterone [74].
Subsequent increase in the levels of these hormones is directly
responsible for the symptoms in Bartter III syndrome.
Bartter IV syndrome is caused by a mutation in barttin (Table
1). A lack of functional barttin causes inhibition of Cl− channel
activity in both ClC-Ka and ClC-Kb [75]. Furthermore, because
both channels are expressed in kidney and the inner ear, the
symptoms of Bartter IV syndrome are severe [76]. The disease
is characterized by congenital deafness, increased urine flow,
excessive thirst and a failure to thrive. This syndrome is also
known as Bartter syndrome with sensorineurial deafness
(BSND) [77]. Although, the physiology of hearing is not
completely understood, it appears that Cl− channels may
provide an efficient mechanism for Cl− recycling at the
basolateral membrane of stria vascularis in the inner ear. This
recycling is important for homeostasis of K+ ions in the inner
ear fluid, which is essential for proper hearing [75].
3. Dysfunction of Cl− channels in intracellular membranes
3.1. Osteopetrosis
Osteopetrosis is a disorder characterized by dense and fragile
bones devoid of bone marrow [78]. Genetic studies have
identified mutations in human CLCN7 gene that encodes the
ClC-7 channel, which can induce different forms of osteope-
trosis (Table 1). There are two forms of osteopetrosis.
Autosomal-dominant osteopetrosis is characterized by sclerosis,
predominantly involving the spine, the pelvis and the skull base
[79–81]. An autosomal-recessive mutation leads to severe and
intermediate osteopetrosis [82]. Homozygous mutations lead to
malignant infantile osteopetrosis [82], while patients with
heterozygous, dominant mutations suffer from a less severe
form [83].
The ClC-7 channel resides in membranes of the late
endosomes and lysosomes in osteoclasts. Osteoclasts play a
key role in the bone resorption during adult life [84]. These cells
degrade the bone mineral through acidification. The bone
degradation is mediated through exocytosis of a large number of
intracellular vesicles that fuse with bone-facing plasma
membrane to form a ruffled border membrane, which is the
actual resorbing organelle [85]. Activation of ClC-7 channels in
intracellular vesicles of healthy subjects provides the Cl−
conductance required for efficient proton pumping by the H+-
ATPase [82]. Exocytic insertion of H+-ATPase and ClC-7 into
the ruffled border membrane results in acidification of theresorption lacuna which promotes the dissolution of the mineral
phase and the enzymatic degradation of the organic bone
matrix. A loss of the ClC-7 channel activity leads to a defect in
bone degradation and the development of osteopetrosis [86].
3.2. DentTs disease
Dent's disease, also known as X-linked recessive nephro-
lithiasis, is an inherited disorder caused by mutations in the gene
CLCN5 that encodes the Cl− channel ClC-5 [87] (Table 1). This
disease is characterized by low-molecular weight proteinuria,
hyperphosphaturia and hypercalciuria, which leads to the
formation of kidney stones [88]. The ClC-5 channel resides in
the endosomal membrane and plays a key role in the
acidification of these compartments in proximal renal tubules.
Recent studies indicate that many ClC channels including ClC-
5 which are similar to the bacterial homolog ClC-e1, may also
function as a Cl−/H+ exchange transporter [89]. In any case, it
appears that the influx of Cl− into the endosomal compartment
through ClC-5 provides the negative ion which is essential for
electrical neutralization of the proton influx generated either by
H+-ATPase or ClC-5 itself [87].
There is emerging evidence that a loss of ClC-5 channel
activity inhibits endocytosis of parathyroid hormone and
vitamin D as well as receptor-mediated and fluid-phase
endocytosis. Over time these changes result in a severe loss
of proteins and the formation of kidney stones [90]. Genetic
studies have shown that the elimination of ClC-5 in knock-out
mice reproduced the low-molecular weight proteinuria ob-
served in patients with Dent's disease [91]. These findings have
firmly established that a loss of ClC-5 channel activity plays a
key role in the pathogenesis of Dent's disease.
4. Stimulation of Cl− channel activity
4.1. Glioma
Gliomas are a heterogeneous group of primary brain tumors
derived from glial cells. These cells exhibit uncontrolled
proliferation, and have the ability to disperse from the tumor
site and invade the healthy brain tissue [92]. Glioma cells
squeeze through narrow extracellular brain spaces by rapidly
changing cell volume. Notably, these changes are inhibited by
Cl− channel blockers that render glioma cells unable to invade
[5,93]. Glioma cells also have the capacity to thrive in the
vicinity of an edematous environment. Under conditions of the
decreased osmolarity in extracellular media, glioma cells can
rapidly regulate their volume back to the baseline levels through
stimulation of plasma membrane Cl− channels. Thus, it appears
that the functional interactions between changes in cell volume
and volume-activated Cl− channels in glioma cells is important
for proliferation and the growth of glioma in the brain.
Recent studies indicate that ClC-2 and ClC-3 channels may
contribute to the ability of glioma cells to invade the healthy
brain [6]. However, many studies have demonstrated that ClC-2
and ClC-3 are no longer the molecular candidates for volume-
regulated Cl− channels [4]. Thus, the molecular identity of Cl−
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4.2. Malaria
The malaria parasite (Plasmodium falciparum) in the course
of its complex life cycle invades red blood cells (RBCs) of its
vertebrate host [94]. This intra-erythrocytic phase of the parasite
life cycle is responsible for all symptoms of malaria, a disease
that causes close to five billion episodes of clinical illness and
up to three million deaths each year [95,96].
The cellular mechanisms responsible for the growth of the
malaria parasite are poorly understood [97]. The malaria
parasite remodels RBCs to provide nutrients for its own needs
[94]. There is emerging evidence that stimulation of Cl−
channel activity in the plasma membrane of RBCs contributes
importantly to the growth of the malaria parasite [7,8,98,99].
Two models have been proposed to explain the growth of
malaria parasite. According to the first model, infection with the
malaria parasite upregulates endogenous Cl− channels in the
RBCs which promotes the growth of the parasite [99]. Recent
studies have demonstrated that infection with the malaria
parasite leads to upregulation of endogenous ClC-2 channel.
Surprisingly, a loss of ClC-2 channel activity in ClC-2 knockout
mice had no effect on intraerythrocytic parasite survival [100].
Similarly, a loss of CFTR activity in the erythrocytes from CF
patients had no effect on growth of the malaria parasite in vitro
[101]. Thus, the role of endogenous RBC's Cl− channels in the
progression of malaria is still unknown. In the second model, a
parasite-encoded Cl− channel may contribute to the growth of
the malaria parasite. Recent genetic studies have identified a
novel gene in the parasite genome which encodes a distinct Cl−
channel, named plasmodium surface anion channel (PSAC) [7,
98]. Upon infection, PSAC is expressed and inserted into the
plasma membrane, resulting in stimulation of Cl− channel
activity in the infected RBCs [7].
5. Conclusions and perspectives
It is well documented that mutations in the genes encoding
Cl− channels contribute importantly to the pathogenesis of a
broad spectrum of diseases. A loss of Cl− channel activity in the
plasma membrane is linked to the development of diseases
associated with defective transepithelial salt transport, muscle
and neuronal excitability. Dysfunction of Cl− channels in the
intracellular compartments leads to osteopetrosis and Dent's
disease. Although a loss of Cl− channel activity appears to be
the underlying mechanism for the progression of many diseases,
some diseases such as glioma and malaria may develop as a
result of stimulation of Cl− channel activity.
With the application of recently developed biophysical
techniques and gene technologies to study the physiologic
functions of ion channels in greater detail, there has been
remarkable progress in understanding of the roles of Cl−
channels in the pathogenesis of human diseases [4]. Conse-
quently, Cl− channels are emerging as potential pharmacolog-
ical targets for the treatment of many diseases. Despite thisprogress, precise biological functions of Cl− channels in the
physiology of different organs are still poorly understood. Thus,
future studies aimed to define these functions may open new
avenues for developing novel therapies for the treatment of
human diseases.
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